Goldman Sachs Starts ARIAD Pharmaceuticals (ARIA) at Neutral
Tweet Send to a Friend
Goldman Sachs initiates coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Neutral. PT $20.00.
With shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
With shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
